Display options
Cite
Jarecki P, Herman WA, Pawliczak E, et al. Can Low SHBG Serum Concentration Be A Good Early Marker Of Male Hypogonadism In Metabolic Syndrome?. Diabetes Metab Syndr Obes. 2019;12:2181-2191doi: 10.2147/DMSO.S218545.
Jarecki, P., Herman, W. A., Pawliczak, E., & Lacka, K. (2019). Can Low SHBG Serum Concentration Be A Good Early Marker Of Male Hypogonadism In Metabolic Syndrome?. Diabetes, metabolic syndrome and obesity : targets and therapy, 122181-2191. https://doi.org/10.2147/DMSO.S218545
Jarecki, Piotr, et al. "Can Low SHBG Serum Concentration Be A Good Early Marker Of Male Hypogonadism In Metabolic Syndrome?." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 12 (2019): 2181-2191. doi: https://doi.org/10.2147/DMSO.S218545
Jarecki P, Herman WA, Pawliczak E, Lacka K. Can Low SHBG Serum Concentration Be A Good Early Marker Of Male Hypogonadism In Metabolic Syndrome?. Diabetes Metab Syndr Obes. 2019 Oct 21;12:2181-2191. doi: 10.2147/DMSO.S218545. eCollection 2019. PMID: 31695461; PMCID: PMC6814954.
Copy Download .nbib Format: NLM
Share it on

Diabetes Metab Syndr Obes. 2019 Oct 21;12:2181-2191. doi: 10.2147/DMSO.S218545. eCollection 2019.

Can Low SHBG Serum Concentration Be A Good Early Marker Of Male Hypogonadism In Metabolic Syndrome?.

Diabetes, metabolic syndrome and obesity : targets and therapy

Piotr Jarecki, Waldemar A Herman, Elżbieta Pawliczak, Katarzyna Lacka

Affiliations

  1. Student Scientific Club of Endocrinology, Poznan University of Medical Sciences, Pozna?, Wielkopolskie, Poland.
  2. Outpatients Clinic of Endocrine Diseases, Wschowa, Lubuskie, Poland.
  3. Department of Nephrology, Transplantology and Internal Medicine, Poznan University of Medical Sciences, Pozna?, Wielkopolskie, Poland.
  4. Department of Endocrinology, Metabolism and Internal Medicine, Pozna? University of Medical Sciences, Pozna?, Wielkopolskie, Poland.

PMID: 31695461 PMCID: PMC6814954 DOI: 10.2147/DMSO.S218545

Abstract

INTRODUCTION: In men suffering from metabolic syndrome, accompanying insulin resistance may result in a lowering of sex hormone-binding globulin (SHBG) plasma levels and cause changes in their androgenic status.

AIM: The objective of the research was to assess selected androgens and SHBG plasma levels in males meeting diagnostic criteria for MS compared to healthy males.

PATIENTS AND METHODS: The group consisted of 65 men aged between 40 and 70 years old fitting IDF metabolic syndrome criteria and 84 controls. Dehydroepiandrosterone (DHEA) and its sulphate (DHEA-S), total and free testosterone and SHBG serum levels were evaluated. Calculated free and bioavailable testosterone were estimated using an algorithm proposed by the International Society for the Study of the Aging Male.

RESULTS: Men diagnosed with MS showed a statistically significant decrease in plasma levels of DHEA in comparison to healthy ones: 11.579 (8.39-15.56) vs 14.014 (9.611-17.125) ng/mL; p = 0.0350, SHBG: 47.46 (35.78-62.83) vs 71.965 (54.45-91.56) nM/L; p<0.0001 and total testosterone: 5.2 (3.8-6.5) vs 6.3 (5.4-8.25) ng/mL; p = 0.0001 (values presented as a median with Q1-Q3).

CONCLUSION: The results suggest that SHBG is a good early marker for metabolic dysregulation in MS, considering its strength of association and significance is comparable to, or better than, those of MS criteria.

© 2019 Jarecki et al.

Keywords: CRP; DHEA; MS; androgens; cholesterol; testosterone

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

  1. Aging (Albany NY). 2011 May;3(5):533-42 - PubMed
  2. J Clin Endocrinol Metab. 1972 Apr;34(4):730-5 - PubMed
  3. Hormones (Athens). 2010 Oct-Dec;9(4):326-31 - PubMed
  4. J Diabetes Res. 2018 Jul 2;2018:4926789 - PubMed
  5. J Clin Endocrinol Metab. 2006 Mar;91(3):843-50 - PubMed
  6. Metabolism. 2003 Jun;52(6):724-30 - PubMed
  7. Diabetes. 2012 Feb;61(2):372-82 - PubMed
  8. Clin Chem. 2000 Jul;46(7):934-8 - PubMed
  9. Steroids. 2008 Feb;73(2):209-15 - PubMed
  10. J Clin Endocrinol Metab. 1995 Feb;80(2):654-8 - PubMed
  11. Obes Res. 2003 Jun;11(6):689-94 - PubMed
  12. J Clin Pharmacol. 1999 Apr;39(4):327-48 - PubMed
  13. Clin Endocrinol (Oxf). 2015 Dec;83(6):828-33 - PubMed
  14. PLoS One. 2014 Jul 14;9(7):e100409 - PubMed
  15. Eur J Endocrinol. 2004 Dec;151(6):717-25 - PubMed
  16. Diabetes Care. 2011 Nov;34(11):2464-70 - PubMed
  17. Am J Gastroenterol. 2019 May;114(5):758-763 - PubMed
  18. Exp Clin Endocrinol Diabetes. 2011 Jul;119(7):423-30 - PubMed
  19. Cancer. 2006 Feb 1;106(3):581-8 - PubMed
  20. J Clin Endocrinol Metab. 2001 Feb;86(2):724-31 - PubMed
  21. Vitam Horm. 2018;108:29-73 - PubMed
  22. Circulation. 2009 Oct 20;120(16):1640-5 - PubMed
  23. Mol Cell Endocrinol. 2010 Jan 15;314(1):1-16 - PubMed
  24. Metabolism. 1997 May;46(5):526-9 - PubMed
  25. Metabolism. 1990 Sep;39(9):897-901 - PubMed
  26. J Clin Endocrinol Metab. 1980 Jul;51(1):35-40 - PubMed
  27. Metabolism. 1997 Apr;46(4):410-3 - PubMed
  28. Clin Endocrinol (Oxf). 2017 Nov;87(5):523-531 - PubMed
  29. Sao Paulo Med J. 2014;132(2):111-5 - PubMed
  30. Diabetes. 2009 Sep;58(9):2027-31 - PubMed
  31. Diabetes Care. 2010 Jul;33(7):1618-24 - PubMed
  32. Fertil Steril. 2001 Oct;76(4):730-5 - PubMed
  33. J Clin Endocrinol Metab. 2007 Sep;92(9):3568-72 - PubMed
  34. Endocrine. 2018 Aug;61(2):194-203 - PubMed
  35. J Am Geriatr Soc. 2006 Dec;54(12):1832-8 - PubMed
  36. Clin Biochem. 2015 May;48(7-8):503-7 - PubMed
  37. Ann Rheum Dis. 2005 May;64(5):765-6 - PubMed
  38. J Clin Endocrinol Metab. 2002 Feb;87(2):589-98 - PubMed
  39. J Clin Invest. 2007 Dec;117(12):3979-87 - PubMed
  40. Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S64-70 - PubMed
  41. Sci Rep. 2019 Jan 9;9(1):4 - PubMed
  42. J Clin Endocrinol Metab. 1980 Sep;51(3):508-12 - PubMed
  43. N Engl J Med. 2009 Sep 17;361(12):1152-63 - PubMed
  44. Metabolism. 2005 Aug;54(8):1034-40 - PubMed
  45. J Clin Invest. 1994 Oct;94(4):1484-9 - PubMed
  46. Mol Endocrinol. 2002 Oct;16(10):2181-7 - PubMed
  47. J Clin Endocrinol Metab. 1995 Feb;80(2):700-6 - PubMed
  48. Hum Mol Genet. 2010 Feb 1;19(3):535-44 - PubMed
  49. J Endocrinol. 1996 Sep;150 Suppl:S155-64 - PubMed
  50. J Clin Endocrinol Metab. 2002 Aug;87(8):3632-9 - PubMed
  51. Andrology. 2014 Mar;2(2):212-8 - PubMed
  52. J Endocrinol. 2002 Oct;175(1):113-20 - PubMed
  53. J Clin Endocrinol Metab. 2000 Sep;85(9):3276-82 - PubMed
  54. Lancet. 2005 Apr 16-22;365(9468):1415-28 - PubMed
  55. Clin Endocrinol (Oxf). 1997 Jan;46(1):93-100 - PubMed
  56. J Clin Endocrinol Metab. 1996 May;81(5):1821-6 - PubMed
  57. Diabetes Care. 2004 May;27(5):1036-41 - PubMed
  58. Am J Med. 1982 Oct;73(4):506-19 - PubMed
  59. Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S59-63 - PubMed
  60. J Clin Endocrinol Metab. 1988 Sep;67(3):460-4 - PubMed
  61. Diabetes Res Clin Pract. 2014 Aug;105(2):141-50 - PubMed
  62. Eur J Clin Invest. 2010 Mar;40(3):220-5 - PubMed

Publication Types